Recent Updates
Recently added Catalysts
NDRA Positive Sentiment

ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update

Key Takeaway: ENDRA Life Sciences reported its financial results for Q3 2026, highlighting its ongoing development of a third-generation ultrasound product. The company also emphasized its focus on managing operating costs. These efforts reflect ENDRA's commitment to advancing its technology for steatotic liver disease detection.

Market Sentiment Analysis

POSITIVE FACTORS

  • Reported continued development of third-generation ultrasound product.
  • Managed operating costs effectively during the quarter.

Full Press Release Details

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the third quarter ended September 30, 2026, and provided a business update. Business Update During the third quarter of 2026, ENDRA continued to manage its operating costs while continue to develop its third-generation ultrasound product. At th

Frequently Asked Questions

What were ENDRA's financial results for Q3 2026?

ENDRA reported its financial results for the third quarter ended September 30, 2026.

What product is ENDRA developing?

ENDRA is developing a third-generation ultrasound product.

How is ENDRA managing its costs?

The company is focused on managing its operating costs effectively.

What disease does ENDRA's technology target?

ENDRA's technology targets steatotic liver disease (SLD).

Last updated: Nov 16, 2026